Evidence for a role of toll-like receptor 4 in development of chronic allograft rejection after cardiac transplantation

Transplantation

Volumn 78, Issue 9, 2004, Pages 1324-1331

  Methe, Heiko ^a,b   Zimmer, Edgar ^a   Grimm, Cornelia ^a   Nabauer, Michael ^a   Koglin, Joerg ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

Author keywords

Allograft vasculopathy; Heart transplant; Innate immunity; Toll like receptors

Indexed keywords

ACETYLCHOLINE; B7 ANTIGEN; INTERLEUKIN 12; MESSENGER RNA; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CYTOKINE RELEASE; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEART TRANSPLANTATION; HUMAN; IMMUNITY; MALE; MONOCYTE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR DISEASE;

ADULT; AGED; ANIMALS; ANTIGENS, CD14; ANTIGENS, CD80; CHRONIC DISEASE; ENDOTHELIUM, VASCULAR; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNITY, NATURAL; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MIDDLE AGED; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; TRANSPLANTATION, HETEROTOPIC; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8644221278     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000137930.40597.03     Document Type: Article

References (36)

1. Kimbrell DA, Beutler B. The evolution and genetics of innate immunity. Nat Rev Genet 2001; 2: 256.
2. Xu Y, Tao X, Shen B, et al. Structural basis for signal transduction by the toll/interleukin-1 receptor domains. Nature 2000; 408: 111.
3. Ohashi K, Burkart V, Flohe S, et al. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164: 558.
4. Vabulas RM, Ahmad-Nejad P, da Costa C, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001; 276: 31332.
5. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001; 167: 2887.
6. Okamura Y, Watari M, Jerud ES, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276: 10229.
7. Miller YI, Viriyakosol S, Binder CJ, et al. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem 2003; 278; 1561.
8. Johnson GB, Brunn GJ, Kodaira Y, et al. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002; 168: 5233.
9. Schuster JM, Nelson PS. Toll receptors: an expanding role in our understanding of human disease. J Leukoc Biol 2000; 67: 767.
10. Fox-Marsh A, Harrison LC. Emerging evidence that molecules expressed by mammalian tissue grafts are recognized by the innate immune system. J Leukoc Biol 2002; 71: 401.
11. Johnson GB, Brunn GJ, Tang AH, et al. Evolutionary clues to the functions of the toll-like family as surveillance receptors. Trends Immunol 2003; 24: 19.
12. Johnson GB, Brunn GJ, Platt JL. Activation of mammalian Toll-like receptors by endogenous agonists. Crit Rev Immunol 2003; 23: 15.
13. Koglin J, Russell ME. Alloimmune-mediated apoptosis: comparison in mouse models of acute and chronic cardiac rejection. Transplantation 1999; 67: 904.
14. Weis M, Wildhirt SM, Schulze C, et al. Modulation of coronary vasomotor tone by cytokines in cardiac transplant recipients. Transplantation 1999; 68: 1263.
15. Hodgson JM, Marshall JJ. Direct vasoconstriction and endothelium- dependent vasodilation. Mechanisms of acetylcholine effects on coronary flow and arterial diameter in patients with nonstenotic coronary arteries. Circulation 1989; 79: 1043.
16. Weis M, Wildhirt SM, Schulze C, et al. Coronary vasomotor dysfunction in the cardiac allograft: impact of different immunosuppressive regimens. J Cardiovasc Pharmacol 2000; 36: 776.
17. Koglin J, Glysing-Jensen T, Mudgett JS, et al. NOS2 mediates opposing effects in models of acute and chronic cardiac rejection: insights from NOS2-knockout mice. Am J Pathol 1998; 153: 1371.
18. Koglin J, Glysing-Jensen T, Mudgett JS, et al. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation 1998; 97: 2059.
19. Raisanen-Sokolowski A, Glysing-Jensen T, Mottram PL, et al. Sustained anti-CD4/CD8 treatment blocks inflammatory activation and intimal thickening in mouse heart allografts. Arterioscler Thromb Vasc Biol 1997; 17: 2115.
20. Koglin J, Glysing-Jensen T, Gadiraju S, et al. Attenuated cardiac allograft vasculopathy in mice with targeted deletion of the transcription factor STAT4. Circulation 2000; 101: 1034.
21. Shi C, Lee WS, He Q, et al. Immunologic basis of transplant-associated arteriosclerosis. Proc Natl Acad Sci USA 1996; 93: 4051.
22. Salomon RN, Hughes CC, Schoen FJ, et al. Human coronary transplantation-associated arteriosclerosis. Evidence for a chronic immune reaction to activated graft endothelial cells. Am J Pathol 1991; 138: 791.
23. He H, Stone JR, Perkins DL. Analysis of robust innate immune response after transplantation in the absence of adaptive immunity. Transplantation 2002; 73: 853.
24. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol 2001; 1(2): 135.
25. Heine H, Lien E. Toll-like receptors and their function in innate and adaptive immunity. Int Arch Allergy Immunol 2003; 130: 180.
26. Gullestad L, Simonsen S, Ueland T, et al. Possible role of proinflammatory cytokines in heart allograft coronary artery disease. Am J Cardiol 1999; 84: 999.
27. Holm T, Aukrust P, Andreassen AK, et al. Peripheral endothelial dysfunction in heart transplant recipients: possible role of proinflammatory cytokines. Clin Transplant 2000; 14: 218.
28. Manna PP, Steward N, Lowell J, et al. Differentiation and functional maturation of human CD14(+) adherent peripheral blood monocytes by xenogeneic endothelial cells: up-regulation of costimulation, cytokine generation, and toll-like receptors. Transplantation 2002; 74: 243.
29. Dybdahl B, Wahba A, Lien E, et al. Inflammatory response after open heart surgery: release of heat-shock protein 70 and signaling through toll-like receptor-4. Circulation 2002; 105: 685.
30. Tsoulfas G, Takahashi Y, Ganster RW, et al. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 2002; 74: 7.
31. Palmer SM, Burch LH, Davis RD, et al. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003; 168(6): 628.
32. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347: 185.
33. Goldstein DR, Tesar BM, Akira S, et al. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 2003; 111: 1571.
34. Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104: 3091.
35. Marti, V, Romeo I, Aymat R, et al. Coronary endothelial dysfunction as a predictor of intimal thickening in the long term after heart transplantation. J Thorac Cardiovasc Surg 2001; 122: 1174.
36. Hollenberg SM, Klein LW, Parrillo JE, et al. Changes in coronary endothelial function predict progression of allograft vasculopathy after heart transplantation. J Heart Lung Transplant 2004; 23: 265.